Whitehawk Therapeutics, Inc.

WHWK Healthcare Biotechnology

Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.

2.89 0.15 −4.93%
Market cap
$173.3M
P/E
0.0×
Fwd P/E
−3.2×
Dividend yield
—
F-score
4/9
Altman Z
1.52
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
16.76 10.26 11.36 17.38
Net Debt/EBITDA
8.03 5.67 5.16 10.29
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.22) (0.28) (0.32) (0.18)
Book value per Share
2.27 2.20 1.68 2.21
Free Cash Flow
(15.38) (17.23) (22.21) (14.53)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates